celecoxib has been researched along with Acute Lymphoid Leukemia in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with celecoxib also restored GSK3β function and led to down-regulation of β-catenin activity through transcriptional and post-translational mechanisms, two effects likely to contribute to Ph+ cell growth suppression by celecoxib." | 1.43 | Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. ( Calabretta, B; Canonico, PL; Condorelli, F; De Dominici, M; Genazzani, AA; Gnemmi, I; Mariani, SA; Minassi, A; Minieri, V; Riva, B; Salomoni, P, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Riva, B | 1 |
| De Dominici, M | 1 |
| Gnemmi, I | 1 |
| Mariani, SA | 1 |
| Minassi, A | 1 |
| Minieri, V | 1 |
| Salomoni, P | 1 |
| Canonico, PL | 1 |
| Genazzani, AA | 1 |
| Calabretta, B | 1 |
| Condorelli, F | 1 |
| Johansson, AS | 1 |
| Pawelzik, SC | 1 |
| Larefalk, A | 1 |
| Jakobsson, PJ | 1 |
| Holmberg, D | 1 |
| Lindskog, M | 1 |
2 other studies available for celecoxib and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Lymphoblastic T-cell lymphoma in mice is unaffected by Celecoxib as single agent or in combination with cyclophosphamide.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2009 |